Replacing estrogen after menopause is the most effective way to ease hot flashes, protect bone, and restore vaginal and urinary tissue. Its effects on heart, brain, and lifespan depend heavily on starting early and which form is used. Swallowed estrogen raises clot and stroke risk; skin-delivered estrogen and an added uterus-protecting hormone soften these concerns. (Full Review)

Protocol

Estradiol

Transdermal 25–50 mcg/day or oral 0.5–1 mg/day

Titrated to symptom relief

Progesterone

Micronized, for any woman with a uterus

100 mg nightly, or 200 mg 12 days/month

Dosing schedule

Patch twice weekly; oral once daily

Oral estradiol morning, progesterone at night

Time to effect

Hot flashes

1–2 weeks

Stabilizes by 4–8 weeks

Bone protection

Months to years

Silent; accrues over time

Vaginal symptoms

Several weeks

With local estrogen

Benefits

High: Relief of hot flashes and night sweats; prevention of bone loss and fractures; treatment of genitourinary syndrome of menopause

Medium: Reduced all-cause mortality with early initiation; cardiovascular benefit with early initiation; improvement in mood and depressive symptoms during the transition

Low: Reduced risk of type 2 diabetes; reduced colorectal cancer incidence

Speculative: Preservation of cognition and reduced dementia risk; skin and connective tissue maintenance

Contraindications

Current or past estrogen-receptor-positive breast cancer

Active or recent venous thromboembolism

Active liver disease (Child-Pugh B or C)

Unexplained vaginal bleeding

Known or suspected pregnancy

Recent stroke or transient ischemic attack

Active coronary artery disease with recent events (MI <12 months)

Key Interactions

Enzyme-inducing drugs (carbamazepine, phenytoin, rifampin)

CYP3A4 inhibitors (ketoconazole, ritonavir)

Thyroid hormone replacement

St. John's Wort

Phytoestrogens (soy isoflavones, red clover)

Selective estrogen receptor modulators (tamoxifen, raloxifene)

Strong caution: migraine with aura, uncontrolled hypertension

Risk & Side Effects

High: Venous thromboembolism; stroke; breast cancer

Medium: Endometrial cancer; gallbladder disease

Low: Breast tenderness, bloating, and irregular bleeding

Speculative: Ovarian cancer; plaque destabilization with late initiation

Monitoring

Marker	Target	Why
Estradiol (E2)	~50–100 pg/mL on therapy	Confirms absorption and guides dosing
Follicle-stimulating hormone (FSH)	Elevated (>25 IU/L) confirms menopause	Confirms menopausal status at baseline
Lipid panel	LDL <100 mg/dL; triglycerides <100 mg/dL	Oral estrogen can raise triglycerides and shift cholesterol
Bone mineral density (DEXA T-score)	Above −1.0	Tracks fracture-prevention benefit
25-hydroxyvitamin D	40–60 ng/mL	Supports estrogen's bone benefit
Blood pressure	<120/80 mmHg	Stroke risk modifier on systemic estrogen

Cadence: Symptom and blood-pressure review at 6–12 weeks, then annually; bone density every 1–2 years; lipids annually for oral users.

Qualitative Assessment

Vasomotor symptom relief: frequency and severity of hot flashes and night sweats
Sleep quality: continuity and restfulness, particularly resolution of night-sweat-driven awakenings
Mood and energy: stability of mood and daytime energy through the transition
Sexual and urinary comfort: resolution of vaginal dryness, painful intercourse, and recurrent urinary symptoms
Cognitive clarity: subjective focus and memory

Estrogen for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment